Barker Alexandra J, Arthur Agnes, DeNichilo Mark O, Panagopoulos Romana, Gronthos Stan, Anderson Peter J, Zannettino Andrew C W, Evdokiou Andreas, Panagopoulos Vasilios
Musculoskeletal Biology Research Laboratory, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Mesenchymal Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
Bone Rep. 2021 May 27;14:101096. doi: 10.1016/j.bonr.2021.101096. eCollection 2021 Jun.
Bone defects arising from fractures or disease represent a significant problem for surgeons to manage and are a substantial economic burden on the healthcare economy. Recent advances in the development of biomaterial substitutes provides an attractive alternative to the current "gold standard" autologous bone grafting. Despite on-going research, we are yet to identify cost effective biocompatible, osteo-inductive factors that stimulate controlled, accelerated bone regeneration.We have recently reported that enzymes with peroxidase activity possess previously unrecognised roles in extracellular matrix biosynthesis, angiogenesis and osteoclastogenesis, which are essential processes in bone remodelling and repair. Here, we report for the first time, that plant-derived soybean peroxidase (SBP) possesses pro-osteogenic ability by promoting collagen I biosynthesis and matrix mineralization of human osteoblasts . Mechanistically, SBP regulates osteogenic genes responsible for inflammation, extracellular matrix remodelling and ossification, which are necessary for normal bone healing. Furthermore, SBP was shown to have osteo-inductive properties, that when combined with commercially available biphasic calcium phosphate (BCP) granules can accelerate bone repair in a critical size long bone defect ovine model. Micro-CT analysis showed that SBP when combined with commercially available biphasic calcium phosphate (BCP) granules significantly increased bone formation within the defects as early as 4 weeks compared to BCP alone. Histomorphometric assessment demonstrated accelerated bone formation prominent at the defect margins and surrounding individual BCP granules, with evidence of intramembranous ossification. These results highlight the capacity of SBP to be an effective regulator of osteoblastic function and may be beneficial as a new and cost effective osteo-inductive agent to accelerate repair of large bone defects.
由骨折或疾病引起的骨缺损是外科医生面临的重大管理难题,也是医疗经济的沉重负担。生物材料替代品开发方面的最新进展为当前的“金标准”自体骨移植提供了有吸引力的替代方案。尽管研究仍在进行,但我们尚未找到具有成本效益、生物相容性好且能刺激可控、加速骨再生的骨诱导因子。我们最近报道,具有过氧化物酶活性的酶在细胞外基质生物合成、血管生成和破骨细胞生成中具有此前未被认识的作用,这些过程在骨重塑和修复中至关重要。在此,我们首次报道,植物源大豆过氧化物酶(SBP)通过促进人成骨细胞的I型胶原蛋白生物合成和基质矿化而具有促骨生成能力。从机制上讲,SBP调节负责炎症、细胞外基质重塑和骨化的成骨基因,这些基因对于正常骨愈合是必需的。此外,SBP被证明具有骨诱导特性,当与市售双相磷酸钙(BCP)颗粒结合时,可在临界尺寸的长骨缺损绵羊模型中加速骨修复。显微CT分析表明,与单独使用BCP相比,SBP与市售双相磷酸钙(BCP)颗粒结合时,早在4周时就能显著增加缺损内的骨形成。组织形态计量学评估显示,在缺损边缘和单个BCP颗粒周围,骨形成加速显著,并有膜内成骨的证据。这些结果突出了SBP作为成骨细胞功能有效调节剂的能力,作为一种新型且具有成本效益的骨诱导剂,可能有助于加速大骨缺损的修复。